SLC5A2 and hydrops fetalis: The latest evidence from landmark trials suggests that sodium-glucose co-transporter-2 (SGLT-2) inhibitors are beneficial for patients suffering from T2DM or established CVD, mainly HF, by reducing CVD-related morbidity and mortality [16,17].